This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $39.45, marking a -1.42% move from the previous day.
Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs
by Zacks Equity Research
Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%
by Zacks Equity Research
Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote
by Zacks Equity Research
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
Cassava (SAVA) Down on Report of SEC Investigation Into AD Program
by Zacks Equity Research
Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data
by Zacks Equity Research
Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $44.46 in the latest trading session, marking a -0.34% move from the prior day.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $47.17 in the latest trading session, marking a -1.34% move from the prior day.
Cassava Sciences, Inc. (SAVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $50.16 in the latest trading session, marking a +0.95% move from the prior day.
Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $51.08, marking a -0.8% move from the previous day.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Cassava (SAVA) Begins First Efficacy Study on Simufilam in AD
by Zacks Equity Research
Cassava (SAVA) starts a phase III efficacy study evaluating simufilam for treating patients with Alzheimer's disease.
Cassava Sciences, Inc. (SAVA) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $62.08 in the latest trading session, marking a -0.1% move from the prior day.
Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.
Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam
by Zacks Equity Research
Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.
Cassava Sciences, Inc. (SAVA) Stock Moves -0.52%: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $48.26 in the latest trading session, marking a -0.52% move from the prior day.
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $43.95, marking a +0.07% move from the previous day.
Do Options Traders Know Something About Cassava Sciences (SAVA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down
by Zacks Equity Research
Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.
Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.